OTLK

Outlook Therapeutics, Inc.distress 10/10 · high distress / dilution risk

$1.30-3%today-56% from 52w high

outlooktherapeutics.com17 employeesFounded 2010Iselin, NJBiotechnology

Lead: neovascular age-related macular degeneration · est. market ~$12B (approx, global)

Revenue

pre-revenue

Liquidity

$8M

Runway

0.1 yrs

Shares 1y

+172%

Price & events

+154.9% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.0%

-11.0%

-23.5%

+353.0%

+158.4%

-37.5%

-84.7%

-97.3%

-94.6%

All

Overview

Market Cap: $157.12M
Volume: 1.07M
52 Week Range: $0.20 – $2.97
Total Shares: 120.86M
Float Shares: 105.05M
Short %: 10.38%
% Held by Insiders: 17.42%
% Held by Institutions: 6.93%
RVOL: 0.08x
Beta: 0.78

Pipeline stages · 1 programs

bevacizumab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-12

Pipeline · 1 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-12 Estimated 50% readout ~2028-02-14	Phase 3	bevacizumab	Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema	—	active not recruiting

Upcoming readouts & decisions · our signals

1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.

Catalyst news & presentations · 12

2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
July 29, 2026Confirmed 100%PDUFAPDUFAONS-5010 · PDUFA goal date for BLA actionSEC 8-K
June 2026regulatory submissionFiled (NDA/BLA)ONS-5010/LYTENAVA (bevacizumab-vikg) · Company to resubmit BLA as Class 1 resubmissionSEC 8-K
June 1, 2026regulatory submissionFiled (NDA/BLA)ONS-5010 · Resubmission of BLA for ONS-5010/LYTENAVA for nAMDSEC 8-K
May 2026conferencedata presentationsecondaryONS-5010/LYTENAVA (bevacizumab-vikg) · Formal FDA decision on BLA resubmission following FDR meetingSEC 8-K
2026-05-26fda agreementONS-5010/LYTENAVA (bevacizumab-vikg) · FDA granted appeal after Formal Dispute Resolution, concluding substantial evidence of effectiveness for nAMDSEC 8-K
2026-03-05fda agreementONS-5010 · Conducted Type A meeting with FDA to discuss CRLSEC 8-K
2025-12-31crlONS-5010 · FDA issued complete response letter for ONS-5010 BLA resubmission for wet AMD, stating confirmatory evidence of efficacy needed.SEC 8-K
December 31, 2025PDUFAPDUFAONS-5010 · FDA set PDUFA goal date for BLA resubmissionSEC 8-K
before end of calendar year 2025regulatory submissionFiled (NDA/BLA)ONS-5010 · Plan to resubmit BLA for ONS-5010 after FDA Type A meetingSEC 8-K
2025-12-30crlONS-5010/LYTENAVA (bevacizumab-vikg) · Complete Response Letter for BLA resubmission for wet AMDSEC 8-K
2025-08-28crlONS-5010 · FDA issued CRL for ONS-5010 BLA for wet AMD due to lack of substantial evidence of effectiveness.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 120,863,252 · 6 offerings/1y · 1 PIPEs

2026-07-21424B3offering
2026-07-17S-3shelf_registration
2026-05-29424B5offering
2026-05-138-Kmaterial_agreement
2026-05-13424B5offering
2026-04-238-Kprivate_placement
2026-04-23424B5offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

buy · target $6 (+323% upside) · 3 analysts

2026-06-11Ascendiant CapitalBuy
2026-05-18BTIGBuy → Neutral
2026-03-11Ascendiant CapitalBuy
2026-02-18HC Wainwright & Co.Neutral
2026-02-18Chardan CapitalNeutral
2026-01-05Chardan CapitalNeutral

Competitors — neovascular age-related macular degeneration

ABBVAbbVie Inc.$451.1B · D2
AMGNAMGEN INC$195.4B · D3
SNYSanofi$52.5B · D1
OCULOCULAR THERAPEUTIX, INC$1.9B · D2
FDMT4D Molecular Therapeutics, Inc.$524M · D5
OPTEYOpthea Ltd— · D4

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.